Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis

Laboratory Investigation

Volumn 84, Issue 10, 2004, Pages 1339-1351

  Yamanaka, Sumitaka ^a,b   Sunamura, Makoto ^a   Furukawa, Toru ^a   Sun, Libo ^a   Lefter, Liviu P ^a   Abe, Tadayoshi ^a   Yatsuoka, Toshimasa ^a   Fujimura, Hiroko ^a   Shibuya, Emiko ^a   Kotobuki, Noriko ^c   Oshimura, Mitsuo ^c   Sakurada, Akira ^b   Sato, Masami ^b   Kondo, Takashi ^b   Matsuno, Seiki ^a   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Chromosome 12; Pancreatic cancer

Indexed keywords

DNA; MESSENGER RNA;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CHROMOSOME 12; CHROMOSOME 12Q; CONTROLLED STUDY; DNA FINGERPRINTING; DNA MICROARRAY; GENE DELETION; GENE EXPRESSION REGULATION; GENE MAPPING; GROWTH INHIBITION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; ANIMAL; CANCER TRANSPLANTATION; CELL CLONE; CHROMOSOME DELETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HYBRID CELL; METABOLISM; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 12; CLONE CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYBRID CELLS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 4944220115     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700160     Document Type: Article

References (45)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
2. Ariyama J, Suyama M, Ogawa K, et al. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 1990;7:37-47.
3. Beruhe NG, Speevak MD, Chevrette M. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res 1994;54:3077-3081.
4. Luu HH, Zagaja GP, Dubauskas Z, et al. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res 1998;58:3561-3565.
5. Fey MF, Hesketh C, Wainscoat JS, et al. Clonal allele loss in gastrointestinal cancers. Br J Cancer 1989;59:750-754.
6. Sano T, Tsujino T, Yoshida K, et al. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res 1991;51:2926-2931.
7. Schneider BG, Pulitzer DR, Brown RD, et al. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer 1995;13:263-271.
8. Murty VV, Houldsworth J, Baldwin S, et al. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. Proc Natl Acad Sci USA 1992;89:11006-11010.
9. Kimura M, Abe T, Sunamura M, et al. Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a 1-cM region of common allelic loss. Genes Chromosomes Cancer 1996;17:88-93.
10. Fukushige S, Waldman FM, Kimura M, et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997;19:161-169.
11. Heidenblad M, Jonson T, Mahlamaki EH, et al. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 2002;34:211-223.
12. Yatsuoka T, Sunamura M, Furukawa T, et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol 2000;95:2080-2085.
13. Furukawa T, Yatsuoka T, Youssef EM, et al. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet 1998;82:156-159.
14. Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003;162:1807-1815.
15. Sun C, Yamato T, Furukawa T, et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001;8:89-92.
16. Koi M, Morita H, Yamada H, et al. Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. Mol Carcinog 1989;2:12-21.
17. Fournier RE, Ruddle FH. Stable association of the human transgenome and host murine chromosomes demonstrated with trispecific microcell hybrids. Proc Natl Acad Sci USA 1977;74:3937-3941.
18. Kimura M, Furukawa T, Abe T, et al. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res 1998;58:2456-2460.
19. Youssef EM, Kaneko K, Yatsuoka T, et al. Human BAC contig covering the deleted region in pancreatic cancer at 12q21. DNA Seq 2001;11:541-546.
20. van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832-5838.
21. Lefter LP, Furukawa T, Sunamura M, et al. Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. Genes Chromosomes Cancer 2002;34:234-242.
22. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000;60:1111-1116.
23. Schuler GD, Boguski MS, Stewart EA, et al. A gene map of the human genome. Science 1996;274:540-546.
24. Mori Y, Shiwaku H, Fukushige S, et al. Alternative splicing of hMSH2 in normal human tissues. Hum Genet 1997;99:590-595.
25. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977;19:218-235.
26. Tanaka K, Oshimura M, Kikuchi R, et al. Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature 1991;349:340-342.
27. Tanaka K, Yanoshita R, Konishi M, et al. Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 1993;8:2253-2258.
28. Padalecki SS, Johnson-Pais TL, Killary AM, et al. Chromosome 18 suppresses the tumorigenicity of prostate cancer cells. Genes Chromosomes Cancer 2001;30:221-229.
29. Weissman BE, Saxon PJ, Pasquale SR, et al. Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science 1987;236:175-180.
30. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 1990;247:568-571.
31. Matsuura S, Tauchi H, Nakamura A, et al. Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 1998;19:179-181.
32. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
33. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-1202.
34. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812.
35. Holloway S, Davis M, Jaber R, et al. A clinically relevant model of human pancreatic adenocarcinoma identifies patterns of metastasis associated with alterations of the TGF-beta/Smad4 signaling pathway. Int J Gastrointest Cancer 2003;33:61-69.
36. Tseng WW, Deganutti A, Chen MN, et al. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002;6:838-843.
37. Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22:5021-5030.
38. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002;118:52-59.
39. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-4594.
40. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-2896.
41. Zolnierowicz S. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol 2000;60:1225-1235.
42. Ball AR, Schmiesing JA, Zhou C, et al. Identification of a chromosome-targeting domain in the human condensation subunit CNAP1/hCAP-D2/Eg7. Mol Cell Biol 2002;22:5769-5781.
43. Tang Q, Staub CM, Gao G, et al. A novel transforming growth factor-beta receptor-interacting protein that is also a light chain of the motor protein dynein. Mol Biol Cell 2002;13:4484-4496.
44. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002;62:6390-6394.
45. Opdam FJ, Kamps G, Croes H, et al. Expression of Rab small GTPases in epithelial Caco-2 cells: Rab21 is an apically located GTP-binding protein in polarised intestinal epithelial cells. Eur J Cell Biol 2000;79:308-316.